Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Subjects With Advanced Multiple Myeloma.

Next Previous
X
Search
Trial Profile

Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Subjects With Advanced Multiple Myeloma.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elotuzumab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 15 Jan 2018 Results of pooled data from five trials assessing role of elotuzumab in the treatment of relapsed or refractory multiple myeloma, were published in the American Journal of Health-System Pharmacy.
    • 30 Sep 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov record (NCT00425347).
    • 30 Sep 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov record (NCT00425347).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top